Thor Medical ASA (OSE:TRMED), a supplier of alpha-emitters for precision cancer treatment, announced on Thursday that it has signed a five-year supply agreement with AdvanCell, an Australian radiopharmaceutical company, to deliver Thorium-228.
The deal, valued at approximately NOK100m, follows successful deliveries of Thorium-228 samples from Thor Medical's new pilot facilities to AdvanCell earlier this year.
AdvanCell will use the Thorium-228 to produce Pb-212, a key ingredient in its cancer therapies, including ADVC001, which is currently in Phase I/II clinical trials.
This is Thor Medical's third commercial supply agreement this year.
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Eli Lilly and Co receives approval from FDA for Zepbound
YolTech Therapeutics updates data from Phase I/IIa clinical trial of YOLT-201
AstraZeneca's Tagrisso gains EU approval for advanced lung cancer treatment
Novo Nordisk's CagriSema shows superior weight loss in obesity trial
GSK's Jemperli-Zejula combination shows promise in ovarian cancer
Sapience Therapeutics' ST316 receives US FDA Orphan Drug Designation
Ionis Pharmaceuticals' TRYNGOLZA receives US FDA approval
BioArctic licenses PyroGlu-Aβ antibody programme to Bristol Myers Squibb
Thor Medical signs supply deal with AdvanCell
MOBILion Systems collaborates with Dr Oliver Schmitz to enhance metabolomics analysis
Abilita and Orion partner on antibody therapeutics for oncology and pain
Pharus Diagnostics unveils liquid biopsy test for early pancreatic cancer detection
Mendus reports positive topline data from ovarian cancer trial